Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Arena Pharmaceuticals

Share:
Related ARNA
Investing In Marijuana: Cannabis Industry Raises Hit $1.8 Billion, Up 150% Year Over Year
Jim Cramer Gives His Opinion On Allergan, USG And Arena Pharmaceuticals
Pura Vida Investments, Llc Buys Allergan PLC, Nabriva Therapeutics AG, Nabriva Therapeutics AG, ... (GuruFocus)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Arena Pharmaceuticals (NASDAQ: ARNA), but lowered its price target from $20.00 to $14.00.

Jefferies noted, “ARNA reiterated its plans for Belviq (1Q13 U.S. launch) and outlined a new South Korean partnership with Ildong. We remain confident in the long-term potential for Belviq based on combination use with phentermine, but we are lowering our PT from $20 to $14, as we moderate our launch expectations for Belviq monotherapy following disappointing sales for competitor Qsymia.”

Arena Pharmaceuticals closed on Tuesday at $7.60.

Latest Ratings for ARNA

DateFirmActionFromTo
Jul 2017CitigroupMaintainsBuy
Jun 2017CitigroupInitiates Coverage OnBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!

Partner Center